Phosphagenics appoints pharma veteran

By Dylan Bushell-Embling
Tuesday, 08 July, 2008

Phosphagenics [ASX: POH] has appointed Michael Ashton to its board as a non-executive director.

Ashton will also act as a consultant on the Melbourne's company's commercialisation strategies.

Ashton has worked for over three decades in the international pharmaceutical industry, including having held senior management positions at Merck, Pfizer and Faulding.

Ashton also served as CEO for SkyePharma PLC.

Related News

Sunscreen and supplements can lower your vitamin D levels

People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...

Low-dose drug prevents diabetes progression in young people

A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...

Mediterranean-style diet benefits maternal and infant health

Two studies have found that a Mediterranean-style diet benefits maternal health during pregnancy...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd